Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alkermes plc.

NASDAQ: ALKS · Life Sciences · 7 alerts · CIK 1520262

Share price
$46.53Close, Nov 16
Market cap
$7.82B
Shares outstanding
168.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alkermes plc. filings on SEC EDGAR ↗

7:04 AM ET 8-K
Court & Legal Update

Alkermes Court & Legal Update

Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.

Counterparty
Teva Pharmaceuticals, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.